Targeting the nuclear antigen 1 of Epstein-Barr virus to the human endocytic receptor DEC-205 stimulates protective T-cell responses by Cagan Gurer, Till.

Slides:

Advertisements

Similar presentations

Volume 17, Issue 9, Pages (September 2015)

Advertisements

Figure 1. CD11b+CD33+CD14+HLA-DR−/lo myeloid-derived suppressor cell expansion by human immunodeficiency virus.

Supplementary Figure 3 Antigen-specific responses are enhanced by stimulation in an in vitro stimulation (IVS) assay, as well as with stimulation using.

Plasmacytoid dendritic cells efficiently cross-prime naive T cells in vivo after TLR activation by Juliette Mouriès, Gabriel Moron, Géraldine Schlecht,

Cheng-Ming Sun, Edith Deriaud, Claude Leclerc, Richard Lo-Man Immunity

SIV-specific CD8+ T cells express high levels of PD1 and cytokines but have impaired proliferative capacity in acute and chronic SIVmac251 infection by.

High-Risk Acute Lymphoblastic Leukemia Cells with bcr-abl and Ink4a/Arf Mutations Retain Susceptibility to Alloreactive T Cells Faith M. Young, Andrew.

by JoAnn Castelli, Elaine K

Depletion of Alloreactive Donor T Lymphocytes by CD95-Mediated Activation-Induced Cell Death Retains Antileukemic, Antiviral, and Immunoregulatory T Cell.

Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators by Rikke Bæk Sørensen, Sine Reker Hadrup, Inge Marie Svane, Mads Christian.

Defects in T-cell–mediated immunity to influenza virus in murine Wiskott-Aldrich syndrome are corrected by oncoretroviral vector–mediated gene transfer.

by Masih Ostad, Margareta Andersson, Astrid Gruber, and Anne Sundblad

by Rui Zhang, Jeffrey D. Lifson, and Claire Chougnet

Human CD1c+ dendritic cells secrete high levels of IL-12 and potently prime cytotoxic T-cell responses by Giulia Nizzoli, Jana Krietsch, Anja Weick, Svenja.

Maintenance of HCV-specific T-cell responses in antibody-deficient patients a decade after early therapy by Nasser Semmo, Michaela Lucas, George Krashias,

ALK as a novel lymphoma-associated tumor antigen: identification of 2 HLA-A2.1–restricted CD8+ T-cell epitopes by Lorena Passoni, Antonio Scardino, Carla.

Human NK cell development in NOD/SCID mice receiving grafts of cord blood CD34+ cells by Christian P. Kalberer, Uwe Siegler, and Aleksandra Wodnar-Filipowicz.

Simultaneous Ex Vivo Expansion of Cytomegalovirus and Epstein-Barr Virus–Specific Cytotoxic T Lymphocytes Using B-Lymphoblastoid Cell Lines Expressing.

Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses by Madeleine M. Hipp, Norbert Hilf, Steffen.

by Norman Nausch, Ioanna E

by Daniel L. Barber, Katrin D. Mayer-Barber, Lis R. V

Ex vivo induction of multiple myeloma–specific cytotoxic T lymphocytes

Rapid generation of combined CMV-specific CD4+ and CD8+ T-cell lines for adoptive transfer into recipients of allogeneic stem cell transplants by Georg.

Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients by Devi.

Mature dendritic cells pulsed with freeze–thaw cell lysates define an effective in vitro vaccine designed to elicit EBV-specific CD4+ and CD8+ T lymphocyte.

by Éric Aubin, Réal Lemieux, and Renée Bazin

Preactivation with IL-12, IL-15, and IL-18 Induces CD25 and a Functional High-Affinity IL-2 Receptor on Human Cytokine-Induced Memory-like Natural Killer.

Enhancement of the host immune responses in cutaneous T-cell lymphoma by CpG oligodeoxynucleotides and IL-15 by Maria Wysocka, Bernice M. Benoit, Sarah.

Interaction between B7-H1 and PD-1 determines initiation and reversal of T-cell anergy by Fumihiko Tsushima, Sheng Yao, Tahiro Shin, Andrew Flies, Sarah.

HLA-A*0201+ Plasmacytoid Dendritic Cells Provide a Cell-Based Immunotherapy for Melanoma Patients Caroline Aspord, Marie-Therese Leccia, Dimitri Salameire,

Volume 25, Issue 11, Pages (November 2017)

Immunologic potential of donor lymphocytes expressing a suicide gene for early immune reconstitution after hematopoietic T-cell–depleted stem cell transplantation.

FLT3 ligand administration after hematopoietic cell transplantation increases circulating dendritic cell precursors that can be activated by CpG oligodeoxynucleotides.

Myeloid-Derived Suppressor Cells in Psoriasis Are an Expanded Population Exhibiting Diverse T-Cell–Suppressor Mechanisms Lauren Y. Cao, Jin-Sung Chung,

IL-21 inhibits T cell IL-2 production and impairs Treg homeostasis

Regulatory T cells differentially modulate the maturation and apoptosis of human CD8+ T-cell subsets by Maria Nikolova, Jean-Daniel Lelievre, Matthieu.

TGF-β combined with M-CSF and IL-4 induces generation of immune inhibitory cord blood dendritic cells capable of enhancing cytokine-induced ex vivo expansion.

Cytomegalovirus-Specific Cytotoxic T Lymphocytes Can Be Efficiently Expanded from Granulocyte Colony-Stimulating Factor–Mobilized Hemopoietic Progenitor.

Virally infected and matured human dendritic cells activate natural killer cells via cooperative activity of plasma membrane-bound TNF and IL-15 by Lazar.

Application of the ELISPOT assay to the characterization of CD8+ responses to Epstein-Barr virus antigens by Jie Yang, Victor M. Lemas, Ian W. Flinn, Chris.

Inducible Caspase 9 Suicide Gene to Improve the Safety of Allodepleted T Cells after Haploidentical Stem Cell Transplantation Siok-Keen Tey, Gianpietro.

Volume 18, Issue 5, Pages (May 2003)

Kathleen R. Bartemes, BA, Gail M. Kephart, BS, Stephanie J

Human CD8+ memory and EBV-specific T cells show low alloreactivity in vitro and in CD34+ stem cell–engrafted NOD/SCID/IL-2Rγcnull mice Simone Thomas,

Volume 13, Issue 1, Pages (January 2006)

PD‐L1 silencing in antigen presenting DCs results in hyperactivated pro‐inflammatory TCRhigh CD8+ T cells. PD‐L1 silencing in antigen presenting DCs results.

HLA-A*0201+ Plasmacytoid Dendritic Cells Provide a Cell-Based Immunotherapy for Melanoma Patients Caroline Aspord, Marie-Therese Leccia, Dimitri Salameire,

Volume 33, Issue 1, Pages (July 2010)

Volume 24, Issue 2, Pages (February 2006)

Volume 33, Issue 4, Pages (October 2010)

Volume 13, Issue 2, Pages (February 2006)

Volume 135, Issue 3, Pages (September 2008)

by Derek Hoi-Hang Ho, and Roger Hoi-Fung Wong

CD40, but Not CD40L, Is Required for the Optimal Priming of T Cells and Control of Aerosol M. tuberculosis Infection Vanja Lazarevic, Amy J Myers, Charles.

Volume 17, Issue 2, Pages (February 2009)

Eric A Butz, Michael J Bevan Immunity

CTLA-4 Regulates Induction of Anergy In Vivo

T Cells with Low Avidity for a Tissue-Restricted Antigen Routinely Evade Central and Peripheral Tolerance and Cause Autoimmunity Dietmar Zehn, Michael.

Volume 16, Issue 4, Pages (April 2002)

Matthew A. Williams, Eugene V. Ravkov, Michael J. Bevan Immunity

Double-Stranded RNA-Exposed Human Keratinocytes Promote Th1 Responses by Inducing a Type-1 Polarized Phenotype in Dendritic Cells: Role of Keratinocyte-Derived.

Serial vaccination with 32Dp210-derived whole cell vaccines in non-tumor-bearing mice stimulates robust antileukemic cytolytic activity. Serial vaccination.

PD-1 blockade enhances T-cell function.

Notch 1 Signaling Regulates Peripheral T Cell Activation

Toll-Dependent Control Mechanisms of CD4 T Cell Activation

Ex vivo depletion of alloreactive cells based on CFSE dye dilution, activation antigen selection, and dendritic cell stimulation by Wayne R. Godfrey, Mark.

Dissecting the Multifactorial Causes of Immunodominance in Class I–Restricted T Cell Responses to Viruses Weisan Chen, Luis C. Antón, Jack R. Bennink,

Volume 126, Issue 5, Pages (May 2004)

Pretreatment of donor T cells with a c-Rel antagonist does not impair GVT activity. Pretreatment of donor T cells with a c-Rel antagonist does not impair.

LSECtin, expressed by B16 cells, inhibits the tumor-specific immune responses both in vivo and in vitro. LSECtin, expressed by B16 cells, inhibits the.

Presentation transcript:

Targeting the nuclear antigen 1 of Epstein-Barr virus to the human endocytic receptor DEC-205 stimulates protective T-cell responses by Cagan Gurer, Till Strowig, Fabienne Brilot, Maggi Pack, Christine Trumpfheller, Frida Arrey, Chae Gyu Park, Ralph M. Steinman, and Christian Münz Blood Volume 112(4):1231-1239 August 15, 2008 ©2008 by American Society of Hematology

Induction of EBNA1-specific T-cell responses by αDEC-205-EBNA1 targeting to DCs. (A) PBMCs from blood donors were stimulated with mature autologous monocyte-derived DCs that were pulsed with medium, EBNA1 peptides, 1 μg/mL αDEC-205-EBNA1, or control Ig-EBNA... Induction of EBNA1-specific T-cell responses by αDEC-205-EBNA1 targeting to DCs. (A) PBMCs from blood donors were stimulated with mature autologous monocyte-derived DCs that were pulsed with medium, EBNA1 peptides, 1 μg/mL αDEC-205-EBNA1, or control Ig-EBNA1 using poly (I:C) as an adjuvant. After 9 days, frequencies of IFN-γ+ CD3+ T cells were determined by intracellular staining after EBNA1 peptide restimulation (top row). After a second round of stimulation with an EBNA1 peptide library on day 9, proliferation was evaluated by CFSE dilution on day 15 (bottom row). Representative data of 17 experiments are shown. Percentages on plots are of total cells within respective gates. Summary of the EBNA1-specific T-cell responses for 17 donors evaluated (B) by IFN-γ+ secretion on day 9 and (C) by CFSE dilution on day 15. Horizontal lines represent medians. Cagan Gurer et al. Blood 2008;112:1231-1239 ©2008 by American Society of Hematology

Dose-dependent response to αDEC-205-EBNA1 targeting. Dose-dependent response to αDEC-205-EBNA1 targeting. Monocyte-derived DCs were pulsed with increasing concentrations of αDEC-205-EBNA1 (■) or Ig-EBNA1 (♦) control antibodies using poly(I:C) as a maturation stimulus. PBMCs from the same donor were stimulated with the antigen-loaded and matured DCs for 9 days, and frequencies of EBNA1-specific IFN-γ+ CD3+ T cells were determined by intracellular staining after EBNA1 peptide restimulation. One of 2 evaluated donors is shown. Cagan Gurer et al. Blood 2008;112:1231-1239 ©2008 by American Society of Hematology

αDEC-205-EBNA1 in combination with poly(I:C) induces EBNA1-specific T-cell responses in bulk PBMCs. PBMCs from blood donors were pulsed with medium, 5 μg/mL αDEC-205-EBNA1, or isotype-EBNA1 using poly(I:C) as an adjuvant and with 10 U/mL IL-2. αDEC-205-EBNA1 in combination with poly(I:C) induces EBNA1-specific T-cell responses in bulk PBMCs. PBMCs from blood donors were pulsed with medium, 5 μg/mL αDEC-205-EBNA1, or isotype-EBNA1 using poly(I:C) as an adjuvant and with 10 U/mL IL-2. EBNA1-specific (A) IFN-γ production on day 9 and (B) proliferation by T cells on day 15 were determined as in Figure 1 for 6 different donors. Horizontal lines represent medians. Cagan Gurer et al. Blood 2008;112:1231-1239 ©2008 by American Society of Hematology

PBMCs primed by αDEC-205-EBNA1 control EBV infection. PBMCs primed by αDEC-205-EBNA1 control EBV infection. Bulk PBMCs were pulsed with medium, 5 μg/mL αDEC-205-EBNA1, or control Ig-EBNA1 in combination with poly(I:C) and 10 U/mL IL-2. After 9 days, the cells were restimulated and expanded with an EBNA1 peptide library for an additional 6 days at which point autologous EBV-infected B cells were added into the culture and supplemented with 10 U/mL IL-2, 10 ng/mL IL-7, and 10 ng/mL IL-15. (A) After 16 days of coculture, outgrowth of EBV-infected B cells was assessed by flow cytometric analysis of CD19+ CD23+ double-positive cells. Representative data of 6 experiments are shown. Percentages on plots are of total cells within respective gates. (B) Summary of EBV-infected B-cell regression for 6 different donors. Cagan Gurer et al. Blood 2008;112:1231-1239 ©2008 by American Society of Hematology

Induction of primary T- and B-cell responses via αDEC-205-EBNA1 vaccination in immunodeficient mice reconstituted with human immune system components. Induction of primary T- and B-cell responses via αDEC-205-EBNA1 vaccination in immunodeficient mice reconstituted with human immune system components. Reconstituted mice were vaccinated intraperitoneally with PBS, Ig-EBNA1, or αDEC-205-EBNA1 using poly(I:C) as an adjuvant and boosted a month later. Two months after boost, bulk splenocytes were harvested, stimulated with either EBNA1 peptides or an influenza matrix protein 1 peptide library, and subjected to an IFN-γ ELISPOT assay. (A) Ratio of EBNA1-specific IFN-γ spots to nonspecific spots against the influenza peptides summarized for each vaccine group. Horizontal lines represent medians.(B) IFN-γ spots/105 splenocytes and EBNA1 IgM levels shown for 2 animals from each group. An index value of 1.1 or higher confirms the presence of anti-EBNA1 antibodies. Error bars represent SD. Cagan Gurer et al. Blood 2008;112:1231-1239 ©2008 by American Society of Hematology